Erratum: Brain-immune interactions and disease susceptibility (Molecular Psychiatry (2005) 10 (239-250) DOI: 10.1038/sj.mp.4001643);Brain-immune interactions and disease susceptibility

Molecular Psychiatry

Volumn 10, Issue 3, 2005, Pages 239-250

  Marques Deak, A ^a   Cizza, G ^b   Sternberg, E ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Autoimmune disease; Depression; Neuroendocrine; Osteoporosis

Indexed keywords

BETA ENDORPHIN; CORTICOTROPIN; CYTOKINE; DEXAMETHASONE; ESTROGEN; ESTROGEN RECEPTOR; GLUCOCORTICOID; GONADORELIN; GROWTH HORMONE; HYDROCORTISONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 6; LEPTIN; LIOTHYRONINE; PRASTERONE; PROTIRELIN; SOMATOMEDIN C; TESTOSTERONE; THYROID HORMONE; THYROTROPIN; THYROXINE; TUMOR NECROSIS FACTOR ALPHA;

ALLERGIC DISEASE; ALLERGIC ENCEPHALOMYELITIS; ARTHRITIS; ASTHMA; AUTOIMMUNE DISEASE; CROHN DISEASE; CYTOKINE PRODUCTION; DELAYED HYPERSENSITIVITY; DERMATITIS; DEXAMETHASONE SUPPRESSION TEST; HUMAN; HYPOTHALAMUS HYPOPHYSIS GONAD SYSTEM; HYPOTHALAMUS HYPOPHYSIS THYROID SYSTEM; IMMUNE SYSTEM; IMMUNOGLOBULIN PRODUCTION; IMMUNOREGULATION; INFECTION; INFLAMMATORY DISEASE; MAJOR DEPRESSION; MULTIPLE SCLEROSIS; NEUROENDOCRINE SYSTEM; NONHUMAN; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; TH1 CELL; TH2 CELL; THYROIDITIS;

EID: 15944408882     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/sj.mp.4001732     Document Type: Erratum

References (242)

1. Webster JI, Tonelli L, Sternberg EM. Neuroendocrine regulation of immunity. Annu Rev Immunol 2002; 20: 125-163.
2. Cohen N, Kinney S. Exploring the phylogenetic history of neuralimmune system interactions. In: Ader DCRF (ed). Psychoneuroimmunology, 2nd edn, Vol 2. San Diego, CA: Academic Press, 2001, p 856.
3. Dantzer R. Cytokines and sickness behavior. In: Kronfol Z (ed) Cytokines and Mental Health, 1st edn, Vol 1. Kluwer Academic Publishers: Ann Arbor, MI, 2003, p 425.
4. Miller AH, Pariante CM, Pearce BD. Effects of cytokines on glucocorticoid receptor expression and function. Glucocorticoid resistance and relevance to depression. Adv Exp Med Biol 1999; 461: 107-110.
5. Miller AH. Cytokines and sickness behavior: implications for cancer care and control. Brain Behav Immun 2003; 17(Suppl 1): S132-S134.
6. Maier SF, Watkins LR. Cytokines for psychologists: implications of bidirectional immune-to-brain communication for understanding behavior, mood, and cognition. Psychol Rev 1998; 105: 83-107.
7. Licinio J, Wong ML. The role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection. Mol Psychiatry 1999; 4: 317-327.
8. Tracey KJ. The inflammatory reflex. Nature 2002; 420: 853-859.
9. Sanders VM, Kasprowicz DJ, Swanson-Mungerson MA, Podojil JR, Kohm AP. Adaptive immunity in mice lacking the beta(2)-adrenergic receptor. Brain Behav Immun 2003; 17: 55-67.
10. Green PG, Luo J, Heller PH, Levine JD. Further substantiation of a significant role for the sympathetic nervous system in inflammation. Neuroscience 1993; 55: 1037-1043.
11. Levine JD, Dardick SJ, Roizen MF, Helms C, Baubaum AI. Contribution of sensory afferents and sympathetic efferents to joint injury in experimental arthritis. J Neurosci 1986; 6: 3423-3429.
12. Heijnen CJ, Kavelaars A. The importance of being receptive. J Neuroimmunol 1999; 100: 197-202.
13. Moynihan J, Kruszewska B, Madden K, Callahan T. Sympathetic nervous system regulation of immunity. J Neuroimmunol 2004; 147: 87-90.
14. Bulloch K, McEwen BS, Nordbery J, Diwa A, Baird S. Selective regulation of T-cell development and function by calcitonin gene-related peptide in thymus and spleen. An example of differential regional regulation of immunity by the neuroendocrine system. Ann NY Acad Sci 1998; 840: 551-562.
15. Ferreira S, Sachs D, Cunha F, Lorenzetti B. Persistent hyperalgesia and cytokines. In: Saade N, Apkarian A, Jabbur S (eds) Pain and Neuroimmune Interactions, Vol 1. Kluwer Academic/Plenum Publishers: Boston, USA, 1999, p 244.
16. Grimm MC, Newman R, Hassim Z, Cuan N, Connor SJ, Le Y et al. Cutting edge: vasoactive intestinal peptide acts as a potent suppressor of inflammation in vivo by trans-deactivating chemokine receptors. J Immunol 2003; 171: 4990-4994.
17. Rogers TJ, Steele AD, Howard OM, Oppenheim JJ. Bidirectional heterologous desensitization of opioid and chemokine receptors. Ann NY Acad Sci 2000; 917: 19-28.
18. Pedotti R, DeVoss JJ, Youssef S, Mitchell D, Wedemeyer J, Madanat R et al. Multiple elements of the allergic arm of the immune response modulate autoimmune demyelination. Proc Natl Acad Sci USA 2003; 100: 1867-1872.
19. Steinman L. Elaborate interactions between the immune and nervous systems. Nat Immunol 2004; 5: 575-581.
20. Adcock IM, Ito K. Molecular mechanisms of corticosteroid actions. Monaldi Arch Chest Dis 2000; 55: 256-266.
21. Barnes PJ. Anti-inflammatory actions of glucocorticoids: molecular mechansims. Clin Sci 1998; 94: 557-572.
22. Nuclear Receptor Nomenclature Committee. A unified nomenclature system for the nuclear receptor superfamily. Cell 1999; 97: 161-163.
23. Dhabhar FS, McEwen BS. Enhancing versus suppressive effects of stress hormones on skin immune function. Proc Natl Acad Sci USA 1999; 96: 1059-1064.
24. Eskandari F, Webster JI, Sternberg EM. Neural immune pathways and their connection to inflammatory diseases. Arthritis Res Ther 2003; 5: 251-265.
25. Webster JI, Tonelli L, Sternberg EM. Neural immune interactions in inflammatory/autoimmune disease. In: Antel J (ed) Clinical Neuroimmunology. Oxford University Press: Oxford, 2004, in press.
26. DeRijk R, Michelson D, Karp B, Petrides J, Galliven H, Deuster P et al. Exercise and circadian rhythm-induced variations in plasma cortisol differentially regulate interleukin-1 beta (IL-1 beta), IL-6, and tumor necrosis factor-alpha (TNF alpha) production in humans: high sensitivity of TNF alpha and resistance of IL-6. J Clin Endocrinol Metab 1997; 82: 2182-2191.
27. Adcock IM. Molecular mechanisms of glucocorticosteroid actions. Pulmonary Pharmacol Ther 2000; 13: 115-126.
28. Fauci AS. Immunosuppressive and anti-inflammatory effects of glucocorticoids. Monogr Endocrinol 1979; 12: 449-465.
29. Marx J. How the glucocorticoids suppress immunity. Science 1995; 270: 232-233.
30. Wilckens T. Glucocorticoids and immune function: physiological relevance and pathogenic potential of hormonal dysfunction. Trends Pharmacol Sci 1995; 16: 193-197.
31. Levo Y, Harbeck RJ, Kirkpatrick CH. Regulatory effect of hydrocortisone on the in vitro synthesis of IgE by human lymphocytes. Int Arch Allergy Appl Immunol 1985; 77: 413-415.
32. Whitfield JF, MacManus JP, Gillan DJ. The possible mediation by cyclic AMP of the stimulation of thymocyte proliferation by vasopressin and the inhibition of this mitogenic action by thyrocalcitonin. J Cell Physiol 1970; 76: 65-76.
33. Wiegers GJ, Reul JM, Holsboer F, de Kloet ER. Enhancement of rat splenic lymphocyte mitogenesis after short term preexposure to corticosteroids in vitro. Endocrinology 1994; 135: 2351-2357.
34. Forner MA, Barriga C, Rodriguez AB, Ortega E. A study of the role of corticosterone as a mediator in exercise-induced stimulation of murine macrophage phagocytosis. J Physiol 1995; 488: 789-794.
35. Wiegers G, Reul J. Induction of cytokine receptors by glucocorticoids: functional and pathological significance. Trends Pharmacol Sci 1998; 19: 317-321.
36. Wang HC, Klein JR. Immune function of thyroid stimulating hormone and receptor. Crit Rev Immunol 2001; 21: 323-337.
37. Pawlikowski M, Stepien H, Komorowski J. Hypothalamic-pituitary-thyroid axis and the immune system. Neuroimmunomodulation 1994; 1: 149-152.
38. Kruger TE. Immunomodulation of peripheral lymphocytes by hormones of the hypothalamus-pituitary-thyroid axis. Adv Neuroimmunol 1996; 6: 387-395.
39. Kamilaris TC, DeBold CR, Johnson EO, Mamalaki E, Listwak SJ, Calogero AE et al. Effects of short and long duration hypothyroidism and hyperthyroidism on the plasma adrenocorticotropin and corticosterone responses to ovine corticotropin-releasing hormone in rats. Endocrinology 1991; 128: 2567-2576.
40. Cutolo M. The roles of steroid hormones in arthritis. Br J Rheumatol 1998; 37: 597-599,
41. Cutolo M, Wilder RL. Different roles for androgens and estrogens in the susceptibility to autoimmune rheumatic diseases. Rheum Dis Clin N Am 2000; 26: 825-839.
42. Cutolo M, Sulli A, Pizzorni C, Craviotto C, Straub RH et al. Hypothalamic-pituitary-adrenocortical and gonadal functions in rheumatoid arthritis. Ann NY Acad Sci 2003; 992: 107-117.
43. Olsen NJ, Kovacs WJ. Gonadal steroids and immunity. Endocr Rev 1996; 17: 369-384.
44. Haller C, Holzner B, Mur E, Gunther V. The impact of life events on patients with rheumatoid arthritis: a psychological myth? Clin Exp Rheumatol 1997; 15: 175-179.
45. Cutolo M, Foppiani L, Prete C, Ballarino P, Sulli A, Villaggio B et al. Hypothalamic-pituitary-adrenocortical axis function in premenopausal women with rheumatoid arthritis not treated with glucocorticoids. J Rheumatol 1999; 26: 282-288.
46. Wolkowitz O, Reus V. Dehydroepiandrosterone in psychoneuroendocrinology. In: Wolkowitz O, Rothschild A (eds), Psychoneuroendocrinology, Vol 1, 1st edn. American Psychiatric Publishing, Inc.: Washington, DC, 2003, p 588.
47. Flood JF, Roberts E. Dehydroepiandrosterone sulfate improves memory in aging mice. Brain Res 1988; 448: 178-181.
48. Reddy DS, Kaur G, Kulkarni SK. Sigma (sigmal) receptor mediated anti-depressant-like effects of neurosteroids in the Porsolt forced swim test. Neuroreport 1998; 9: 3069-3073.
49. Melchior CL, Ritzmann RF. Dehydroepiandrosterone is an anxiolytic in mice on the-plus maze. Pharmacol Biochem Behav 1994; 47: 437-441.
50. Bologa L, Sharma J, Roberts E. Dehydroepiandrosterone and its sulfated derivative reduce neuronal death and enhance astrocytic differentiation in brain cell cultures. J Neurosci Res 1987; 17: 225-234.
51. Del Cerro S, Garcia-Estrada J, Garcia-Segura LM. Neuroactive steroids regulate astroglia morphology in hippocampal cultures from adult rats. Glia 1995; 14: 65-71.
52. Guazzo EP, Kirkpatrick PJ, Goodyer IM, Shiers HM, Herbert J. Cortisol, dehydroepiandrosterone (DHEA), and DHEA sulfate in the cerebrospinal fluid of man: relation to blood levels and the effects of age. J Clin Endocrinol Metab 1996; 81: 3951-3960.
53. Wolkowitz OM, Reul JM. DHEA as a neurohormone in the treatment of depression and dementia. In: Mischoulon D, Rosenbaum J (eds). Natural Medications for Psychiatric Disorders. Lippincott Willians & Wilkins: New York, 2001; 62-82.
54. Medina KL, Strasser A, Kincade PW. Estrogen influences the differentiation, proliferation, and survival of early B-lineage precursors. Blood 2000; 95: 2059-2067.
55. Kincade PW, Medina KL, Payne KJ, Rossi MI, Tudor KS, Yamashita Y et al. Early B-lymphocyte precursors and their regulation by sex steroids. Immunol Rev 2000; 175: 128-137.
56. Erlandsson MC, Ohlsson C, Gustafsson JA, Carlsten H. Role of oestrogen receptors alpha and beta in immune organ development and in oestrogen-mediated effects on thymus. Immunology 2001; 103: 17-25.
57. Tsigos C, Chrousos GP. Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress. J Psychosom Res 2002; 53: 865-871.
58. Petraglia F, Sutton S, Vale W, Plotsky P. Corticotropin-releasing factor decreases plasma luteinizing hormone levels in female rats by inhibiting gonadotropin-releasing hormone release into hypophysial-portal circulation. Endocrinology 1987; 120: 1083-1088.
59. Rivier C, Rivier J, Vale W. Stress-induced inhibition of reproductive functions: role of endogenous corticotropin-releasing factor. Science 1986; 231: 607-609.
60. Bonavera JJ, Kalra SP, Kalra PS. Mode of action of interleukin-1 in suppression of pituitary LH release in castrated male rats. Brain Res 1993; 612: 1-8.
61. Carroll BJ, Curtis GC, Davies BM, Mendels J, Sugerman AA. Urinary free cortisol excretion in depression. Psychol Med 1976a; 6: 43-50.
62. Carroll BJ, Curtis GC, Mendels J. Neuroendocrine regulation in depression. I. Limbic system-adrenocortical dysfunction. Arch Gen Psychiatry 1976b; 33: 1039-1044.
63. Brown WA, Shuey I. Response to dexamethasone and subtype of depression. Arch Gen Psychiatry 1980; 37: 747-751.
64. Mortola JF, Liu JH, Gillin JC, Rasmussen DD, Yen SS. Pulsatile rhythms of adrenocorticotropin (ACTH) and cortisol in women with endogenous depression: evidence for increased ACTH pulse frequency. J Clin Endocrinol Metab 1987; 65: 962-968.
65. Linkowski P, Van Cauter E, Leclercq R, Desmedt D, Brasseur M, Golstein J et al. ACTH, cortisol and growth hormone 24-hour profiles in major depressive illness. Acta Psychiatr Belg 1985; 85: 615-623.
66. Rubin RT, Poland RE, Lesser IM, Martin DJ. Neuroendocrine aspects of primary endogenous depression. V. Serum prolactin measures in patients and matched control subjects. Biol Psychiatry 1989; 25: 4-21.
67. Yehuda R, Teicher MH, Trestman RL, Levengood RA, Siever LJ. Cortisol regulation in posttraumatic stress disorder and major depression: a chronobiological analysis. Biol Psychiatry 1996; 40: 79-88.
68. Sachar EJ, Hellman L, Fukushima DK, Gallagher TF. Cortisol production in depressive illness. A clinical and biochemical clarification. Arch Gen Psychiatry 1970; 23: 289-298.
69. Maes M, Maes L, Suy E. Symptom profiles of biological markers in depression: a multivariate study. Psychoneuroendocrinology 1990; 15: 29-37.
70. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 2000; 23: 477-501.
71. Deuschle M, Schweiger U, Weber B, Gotthardt U, Korner A, Schmider J et al. Diurnal activity and pulsatility of the hypothalamus-pituitary-adrenal system in male depressed patients and healthy controls. J Clin Endocrinol Metab 1997; 82: 234-238.
72. Halbreich U, Asnis GM, Shindledecker R, Zumoff B, Nathan RS. Cortisol secretion in endogenous depression. I. Basal plasma levels. Arch Gen Psychiatry 1985a; 42: 904-908.
73. Halbreich U, Asnis GM, Shindledecker R, Zumoff B, Nathan RS. Cortisol secretion in endogenous depression. II. Time-related functions. Arch Gen Psychiatry 1985b; 42: 909-914.
74. Pfohl B, Sherman B, Schlechte J, Stone R. Pituitary-adrenal axis rhythm disturbances in psychiatric depression. Arch Gen Psychiatry 1985; 42: 897-903.
75. Posener JA, DeBattista C, Williams GH, Chmura Kraemer H, Kalehzan BM, Schatzberg AF. 24-Hour monitoring of cortisol and corticotropin secretion in psychotic and nonpsychotic major depression. Arch Gen Psychiatry 2000; 57: 755-760.
76. Nemeroff CB, Widerlov E, Bissette G, Walleus H, Karlsson I, Eklund K et al. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science 1984; 226: 1342-1344.
77. Arato M, Banki CM, Nemeroff CB, Bissette G. Hypothalamic-pituitary- adrenal axis and suicide. Ann NY Acad Sci 1986; 487: 263-270.
78. Banki CM, Bissette G, Arato M, O'Connor L, Nemeroff CB. CSF corticotropin-releasing factor-like immunoreactivity in depression and schizophrenia. Am J Psychiatry 1987; 144: 873-877.
79. Banki CM, Karmacsi L, Bissette G, Nemeroff CB. CSF corticotropin- releasing hormone and somatostatin in major depression: response to antidepressant treatment and relapse. Eur Neuropsychopharmacol 1992; 2: 107-113.
80. Krishnan KR, Doraiswamy PM, Lurie SN, Figiel GS, Husain MM, Boyko OB et al. Pituitary size in depression. J Clin Endocrinol Metab 1991; 72: 256-259.
81. Axelson DA, Doraiswamy PM, Boyko OB, Rodrigo Escalona P, McDonald WM, Ritchie JC et al. In vivo assessment of pituitary volume with magnetic resonance imaging and systematic stereology: relationship to dexamethasone suppression test results in patients. Psychiatry Res 1992; 44: 63-70.
82. Amsterdam JD, Marinelli DL, Arger P, Winokur A. Assessment of adrenal gland volume by computed tomography in depressed patients and healthy volunteers: a pilot study. Psychiatry Res 1987; 21: 189-197.
83. Nemeroff CB, Kiishnan KR, Reed D, Leder R, Beam C, Dunnick NR. Adrenal gland enlargement in major depression. A computed tomographic study. Arch Gen Psychiatry 1992; 49: 384-387.
84. Rubin RT, Phillips JJ, Sadow TF, McCracken JT. Adrenal gland volume in major depression. Increase during the depressive episode and decrease with successful treatment. Arch Gen Psychiatry 1995; 52: 213-218.
85. Raadsheer FC, Hoogendijk WJ, Stam FC, Tilders FJ, Swaab DF. Increased numbers of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients. Neuroendocrinology 1994; 60: 436-444.
86. Raadsheer FC, van IIeerikhuize JJ, Lucassen PJ, Hoogendijk WJ, Tilders FJ, Swaab DF. Corticotropin-releasing hormone mRNA levels in the paraventricular nucleus of patients with Alzheimer's disease and depression. Am J Psychiatry 1995; 152: 1372-1376.
87. Nemeroff CB. The role of corticotropin-releasing factor in the pathogenesis of major depression. Pharmacopsychiatry 1988; 21: 76-82.
88. Holsboer-Trachsler E, Stohler R, Hatzinger M. Repeated administration of the combined dexamethasone-human corticotropin releasing hormone stimulation test during treatment of depression. Psychiatry Res 1991; 38: 163-171.
89. Holsboer F, Von Bardeleben U. Serotonin reuptake inhibitors and DST status. Am J Psychiatry 1987; 144: 263-264.
90. Heuser I, Bissette G, Dettling M, Schweiger U, Gotthardt U, Schmidcr J et al. Cerebrospinal fluid concentrations of corticotropin-releasing hormone, vasopressin, and somatostatin in depressed patients and healthy controls: response to amitriptyline treatment. Depress Anxiety 1998; 8: 71-79.
91. De Bellis MD, Gold PW, Geracioti Jr TD, Listwak SJ, Kling MA. Association of fluoxetine treatment with reductions in CSF concentrations of corticotropin-releasing hormone and arginine vasopressin in patients with major depression. Am J Psychiatry 1993; 150: 656-657.
92. Nemeroff CB, Bissette G, Akil H, Fink M. Neuropeptide concentrations in the cerebrospinal fluid of depressed patients treated with electroconvulsive therapy. Corticotrophin-releasing factor, beta-endorphin and somatostatin. Br J Psychiatry 1991; 158: 59-63.
93. Amsterdam JD, Maislin G, Winokur A, Berwish N, Kling M, Gold P. The oCRH stimulation test before and after clinical recovery from depression. J Affect Disord 1988; 14: 213-222.
94. Holsboer F, Spengler D, Heuser I. The role of corticotropin-releasing hormone in the pathogenesis of Cushing's disease, anorexia nervosa, alcoholism, affective disorders and dementia. Prog Brain Res 1992; 93: 385-417.
95. Fava GA, Fabbri S, Sonino N. Residual symptoms in depression: an emerging therapeutic target. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 1019-1027.
96. Nelson JC, Davis JM. DST studies in psychotic depression: a meta-analysis. Am J Psychiatry 1997; 154: 1497-1503.
97. Rush AJ, Giles DE, Schlesser MA, Orsulak PJ, Parker Jr CR, Weissenburger JE et al. The dexamethasone suppression test in patients with mood disorders. J Clin Psychiatry 1996; 57: 470-484.
98. Watson S, Gallagher P, Del-Estal D, Hearn A, Ferrier IN, Young AH. Hypothalamic-pituitary-adrenal axis function in patients with chronic depression. Psychol Med 2002; 32: 1021-1028.
99. van Praag HM. Faulty cortisol/serotonin interplay. Psychopathological and biological characterisation of a new, hypothetical depression subtype (SeCA depression). Psychiatry Res 1996; 65: 143-157.
100. Rybakowski JK, Twardowska K. The dexamethasone/corticotropin-releasing hormone test in depression in bipolar and unipolar affective illness. J Psychiatr Res 1999; 33: 363-370.
101. Kumar A, Alcser K, Grunhaus L, Greden JF. Relationships of the dexamethasone suppression test to clinical severity and degree of melancholia. Biol Psychiatry 1986; 21: 436-444.
102. Lenox RH, Peyser JM, Rothschild B, Shipley J, Weaver L. Failure to normalize the dexamethasone suppression test: association with length of illness. Biol Psychiatry 1985; 20: 333-337.
103. Peeters F, Nicolson NA, Berkhof J. Levels and variability of daily life cortisol secretion in major depression. Psychiatry Res 2004; 126: 1-13.
104. Strickland PL, Deakin JF, Percival C, Dixon J, Gater RA, Goldberg DP. Bio-social origins of depression in the community. Interactions between social adversity, cortisol and serotonin neurotransmission. Br J Psychiatry 2002; 180: 168-173.
105. Scott LV, Salahuddin F, Cooney J, Svec F, Dinan TG. Differences in adrenal steroid profile in chronic fatigue syndrome, in depression and in health. J Affect Disord 1999; 54: 129-137.
106. Maes M, Calabrese J, Meltzer HY. The relevance of the in- vs outpatient status for studies on HPA-axis in depression: spontaneous hypercortisolism is a feature of major depressed inpatients and not of major depression per se. Prog Neuropsychopharmacol Biol Psychiatry 1994; 18: 503-517.
107. Pariante CM, Miller AH. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol Psychiatry 2001; 49: 391-404.
108. Owens MJ, Nemeroff CB. The role of corticotropin-releasing factor in the pathophysiology of affective and anxiety disorders: laboratory and clinical studies. Ciba Found Symp 1993; 172: 296-308, discussion 308-316.
109. De Kloet ER, Vreugdenhil E, Oitzl MS, Joels M. Brain corticosteroid receptor balance in health and disease. Endocr Rev 1998; 19: 269-301.
110. Juruena MF, Cleare AJ, Pariante CM. The hypothalamic pituitary adrenal axis, glucocroticoid receptor function and relevance to depression. Office J Braz Assoc 2004; 26: 180-188.
111. Yehuda R, Boisoneau D, Mason JW, Giller EL. Glucocorticoid receptor number and cortisol excretion in mood, anxiety, and psychotic disorders. Biol Psychiatry 1993; 34: 18-25.
112. Wassef AA, O'Boyle M, Gardner R, Rose RM, Brown A, Harris A et al. Glucocorticoid receptor binding in three different cell types in major depressive disorder: lack of evidence of receptor binding defect. Prog Neuropsychopharmacol Biol Psychiatry 1992; 16: 65-78.
113. Maguire TM, Thakore J, Dinan TG, Hopwood S, Breen KC. Plasma sialyltransferase levels in psychiatric disorders as a possible indicator of HPA axis function. Biol Psychiatry 1997; 41: 1131-1136.
114. Juruena MF, Cleare AJ, Bauer ME, Pariante CM. Molecular mechanism of GR sensitivity and relevant of affective disorders. Acta Neuropsychiatrica 2003; 15: 354-367.
115. Bauer ME, Papadopoulos A, Poon L, Perks P, Lightman SL, Checkley S, Shanks N. Altered glucocorticoid immunoregulation in treatment resistant depression. Psychoneuroendocrinology 2003; 28: 49-65.
116. Cotter PA, Mulligan OF, Landau S, Papadopoulos A, Lightman SL, Checkley SA. Vasoconstrictor response to topical beclomethasone in major depression. Psychoneuroendocrinology 2002; 27: 475-487.
117. Pariante CM, Pearce BD, Pisell TL, Sanchez CI, Po C, Su C, Miller AH. The proinflammatory cytokine, interleukin-1alpha, reduces glucocorticoid receptor translocation and function. Endocrinology 1999; 140: 4359-4366.
118. Rangarajan PN, Umesono K, Evans RM. Modulation of glucocorticoid receptor function by protein kinase A. Mol Endocrinol 1992; 6: 1451-1457.
119. de Castro M, Elliot S, Kino T, Bamberger C, Karl M, Webster F, Chrousos GP. The non-ligand binding beta-isoform of the human glucocorticoid receptor (hGR beta): tissue levels, mechanism of action, and potential physiologic role. Mol Med 1996; 2: 597-607.
120. Bronnegard M, Stierna P, Marcus C. Glucocorticoid resistant syndromes-molecular basis and clinical presentations. J Neuroendocrinol 1996; 8: 405-415.
121. Fraser SA, Kroenke K, Callahan CM, Hui SL, Williams Jr JW, Unutzer J. Low yield of thyroid-stimulating hormone testing in elderly patients with depression. Gen Hosp Psychiatry 2004; 26: 302-309.
122. Boswell EB, Anfinson TH, Nemeroff CB. Depression associated with endocrine disorder. In: Robertson MM, Katona CLE (eds). Depression and Physical Illness. Wiley: Chichester, England, 1997; 256-292.
123. Cleare AJ, McGregor A, O'Keane V. Neuroendocrine evidence for an association between hypothyroidism, reduced central 5-HT activity and depression. Clin Endocrinol (Oxford) 1995; 43: 713-719.
124. Bahls SC, de Carvalho GA. The relation between thyroid function and depression: a review. Rev Bras Psiquiatr 2004; 26: 41-49.
125. Fava M, Labbate LA, Abraham ME, Rosenbaum JF. Hypothyroidism and hyperthyroidism in major depression revisited. J Clin Psychiatry 1995; 56: 186-192.
126. Maes M, Meltzer HY, Cosyns P, Suy E, Schotte C. An evaluation of basal hypothalamic-pituitary-thyroid axis function in depression: results of a large-scaled and controlled study. Psychoneuroendocrinology 1993; 18: 607-620.
127. Baumgartner A, Graf KJ, Kurten I, Meinhold H. The hypothalamic-pituitary- thyroid axis in psychiatric patients and healthy subjects: Parts 1-4. Psychiatry Res 1988; 24: 271-332.
128. O'Connor D, Gwirtsman H, Lossen P. Thyroid function in psychiatry disorders, In: Wolkowitz O, RothschildA (eds), Psychoneuroendocrinology, Vol 1. American Psychiatric Publishing: London, England, 2003, p 588.
129. Briggs J, McBrigc L, Hagino O. Screening depressives for causative medical illness; the example of thyroid testing, II: hypothesis testing in ambulatory depressives. Depression 1993; 1: 220-224.
130. Kirkegaard C, Faber J. Altered serum levels of thyroxine, triiodothyronines and diiodothyronines in endogenous depression. Acta Endocrinol (Copenh) 1981; 96: 199-207.
131. Loosen PT. Hormones of the hypothalamic-pituitary-thyroid axis: a psychoneuroendocrine perspective. Pharmacopsychiatry 1986; 19: 401-415.
132. Loosen PT, Thyroid function in affective disorders and alcoholism. Endocrinol Metab Clin N Am 1988; 17: 55-82.
133. Vandoolaeghe E, Maes M, Vandevyvere J, Neels H. Hypothalamic-pituitary- thyroid-axis function in treatment resistant depression. J Affect Disord 1997; 43: 143-150.
134. Ordas DM, Labbate LA. Routine screening of thyroid function in patients hospitalized for major depression or dysthymia? Ann Clin Psychiatry 1995; 7: 161-165.
135. Gendall KA, Joyce PR, Mulder RT, Luty SE. Thyroid indices and response to fluoxetine and nortriptyline in major depression. J Psychopharmacol 2003; 17: 431-437.
136. Sarandol A, Taneli B, Sivrioglu Y. Hypothalamic-pituitary-adrenal and hypothalamic-pituitary-thyroid axis findings in depressive disorder. Turk Psikiyatri Derg 2003; 14: 116-124.
137. Staner L, Duval F, Haba J, Mokrani MC, Macher JP. Disturbances in hypothalamo pituitary adrenal and thyroid axis identify different sleep EEG patterns in major depressed patients. J Psychiatr Res 2003; 37: 1-8.
138. Fountoulakis KN, Iacovides A, Grammaticos P, St Kaprinis G, Bech P. Thyroid function in clinical subtypes of major depression: an exploratory study. BMC Psychiatry 2004; 4: 6.
139. Carta MG, Loviseili A, Hardoy MC, Massa S, Cadeddu M, Sardu C et al. The link between thyroid autoimmunity (antithyroid peroxidase autoantibodies) with anxiety and mood disorders in the community: a field of interest for public health in the future. BMC Psychiatry 2004; 4: 25.
140. Luo LG, Bruhn T, Jackson IM. Glucocorticoids stimulate thyrotropin-releasing hormone gene expression in cultured hypothalamic neurons. Endocrinology 1995; 136: 4945-4950.
141. Kirkegaard C, Faber J. The role of thyroid hormones in depression. Eur J Endocrinol 1998; 138: 1-9.
142. Altshuler LL, Bauer M, Frye MA, Gitlin MJ, Mintz J, Szuba MP et al. Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature. Am J Psychiatry 2001; 158: 1617-1622.
143. Wick G, Sgonc R, Lechner O. Neuroendocrine-immune disturbances in animal models with spontaneous autoimmune diseases. Ann NY Acad Sci 1998; 840: 591-598.
144. Lechner O, Hu Y, Jafarian Tehrani M, Dietrich H, Schwartz S, Herold M et al. Disturbed immunoendocine communication via the hypothalamo-pituitaty-adrenal axis in murine lupus. Brain Behav Immun 1996; 10: 337-350.
145. Hu Y, Dietrich H, Herold M, Heinrich PC, Wick G. Disturbed immuno-endocrine communication via the hypothalamo-pituitary-adrenal axis in autoimmune disease. Int Arch Allergy Immunol 1993; 102: 232-241.
146. Jafarian Tehrani M, Sternberg EM. Animal models of neuroimmune interaction in inflammatory diseases. J Neuroimmunol 1999; 100: 13-20.
147. Sternberg EM, Hill JM, Chrousos GP, Kamilaris T, Listwak SJ, Gold PW et al. Inflammatory mediator-induced hypothalamic-pituitary-adrenal axis activation is defective in streptococcal cell wall arthritis-susceptible Lewis rats. Proc Natl Acad Sci USA 1989a; 86: 2374-2378.
148. Cash JM, Crofford LJ, Gallucci WT, Sternberg EM, Gold PW, Chrousos GP et al. Pituitary-adrenal axis responsiveness to ovine corticotrophin relearsing hormone in patients with rheumatoid arthritis treated with low dose prednisolone. J Rheumatol 1992; 19: 1692-1696.
149. Chikanza IC. Mechanisms of corticosteroid resistance in rheumatoid arthritis: a putative role for the corticosteroid receptor beta isoform. Ann NY Acad Sci 2002; 966: 39-48.
150. Chikanza IC, Petrou P, Kingsley G, Chrousos GP, Panayi GS, Defective hypothalamic response to immune and inflammatory stimuli in patients with rheumatoid arthritis. Arthritis Rheum 1992; 35: 1281-1288.
151. Eijsbouts AM, Murphy E. The role of the hypothalamic-pituitary-adrenal axis in rheumatoid arthritis. Baillieres Best Pract Res Clin Rheumatol 1999; 13: 599-613.
152. Gutierrez MA, Garcia ME, Rodriguez JA, Mardonez G, Jacobelli S, Rivero S et al. Hypothalamic-pituitary-adrenal axis in patients with active rheumatoid arthritis: a controlled study using insulin hypoglycemia stress test and prolactin stimulation. J Rheumatol 1999; 26: 277-281.
153. Neeck G, Federlin K, Graef V, Rusch D, Schmidt KL. Adrenal secretion of cortisol in patients with rheumatoid arthritis. J Rheumatol 1990; 17: 24-29.
154. Johnson EO, Vlachoyiannopoulos PG, Skopouli FN, Tzioufas AG, Moutsopoulos HM. Hypofunction of the stress axis in Sjogren's syndrome. J Rheumatol 1998; 25: 1508-1514.
155. Gutierrez MA, Garcia ME, Rodriguez JA, Rivero S, Jacobelli S. Hypothalamic-pituitary-adrenal axis function and prolactin secretion in systemic lupus erythematosus. Lupus 1998; 7: 404-408.
156. Wei T, Lightman SL. The neuroendocrine axis in patients with multiple sclerosis. Brain 1997; 120(Part 6): 1067-1076.
157. Michelson D, Stone L, Galliven E, Magiakou MA, Chrousos GP, Sternberg EM et al. Multiple sclerosis is associated with alterations in hypothalamic- pituitary-adrenal axis function. J Clin Endocrinol Metab 1994; 79: 848-853.
158. Buske-Kirschbaum A, Geiben A, Hollig H, Morschhauser E, Hellhammer D. Altered responsiveness of the hypothalamus-pituitary-adrenal axis and the sympathetic adrenomedullary system to stress in patients with atopic dermatitis. J Clin Endocrinol Metab 2002; 87: 4245-4251.
159. Buske-Kirschbaum A, Hellhammer DH. Endocrine and immune responses to stress in chronic inflammatory skin disorders. Ann NY Acad Sci 2003; 992: 231-240.
160. Buske-Kirschbaum A, Jobst S, Psych D, Wustman A, Kirschbaum C, Rauh W et al. Attenuated free cortisol response to psychosocial stress in children with atopic dermatitis. Psychosom Med 1997; 59: 419-426.
161. Demitrack MA, Crofford LJ. Evidence for and pathophysiologic implications of hypothalamic-pituitary-adrenal axis dysregulation in fibromyalgia and chronic fatigue syndrome. Ann NY Acad Sci 1998; 840: 684-697.
162. Crofford LJ. The hypothalamic-pituitary-adrenal axis in the pathogenesis of rheumatic diseases. Endocrinol Metab Clin N Am 2002; 31: 1-13.
163. Demitrack MA. Neuroendocrine correlates of chronic fatigue syndrome: a brief review. J Psychiatr Res 1997; 31: 69-82.
164. Crofford LJ, Pillemer SR, Kalogeras KT, Cash JM, Michelson D, Kling MA et al. Hypothalamic-pituitary-adrenal axis perturbations in patients with fibromyalgia. Arthitis Rheum 1994; 37: 1583-1592.
165. Straub RH, Herfarth H, Falk W, Andus T, Scholmerich J. Uncoupling of the sympathetic nervous system and the hypothalamic-pituitary-adrenal axis in inflammatory bowel disease? J Neuroimmunol 2002a; 126: 116-125.
166. Niess JH, Monnikes H, Dignass AU, Klapp BF, Arck PC. Review on the influence of stress on immune mediators, neuropeptides and hormones with relevance for inflammatory bowel disease. Digestion 2002; 65: 131-140.
167. Crofford LJ, Young EA, Engleberg NC, Korszun A, Brucksch CB, McClure LA et al. Basal circadian and pulsatile ACTH and cortisol secretion in patients with fibromyalgia and/or chronic fatigue syndrome. Brain Behav Immun 2004; 18: 314-325.
168. Cleare AJ. The HPA axis and the genesis of chronic fatigue syndrome. Trends Endocrinol Metab 2004; 15: 55-59.
169. Cleare AJ. The neuroendocrinology of chronic fatigue syndrome. Endocr Rev 2003; 24: 236-252.
170. Gaab J, Huster D, Peisen R, Engert V, Heitz V, Schad T et al. Hypothalamic-pituitary-adrenal axis reactivity in chronic fatigue syndrome and health under psychological, physiological, and pharmacological stimulation. Psychosom Med 2002; 64: 951-962.
171. Neeck G, Crofford LJ. Neuroendocrine perturbations in fibromyalgia and chronic fatigue syndrome. Rheum Dis Clin N Am 2000; 26: 989-1002.
172. DeRijk RH, Schaaf MJ, Turner G, Datson NA, Vreugdenhil E, Cidlowski J et al. A human glucocorticoid receptor gene variant that increases the stability of the glucocorticoid receptor beta-isoform mRNA is associated with rheumatoid arthritis. J Rheumatol 2001; 28: 2383-2388.
173. DeRijk RH, Schaaf M, de Kloet ER. Glucocorticoid receptor variants: clinical implications. J Steroid Biochem Mol Biol 2002; 81: 103-122.
174. Webster JI, Tonelli LH, Moayeri M, Simons Jr SS, Leppla SH, Sternberg EM. Anthrax lethal factor represses glucocorticoid and progesterone receptor activity. Proc Natl Acad Sci USA 2003; 100: 5706-5711.
175. Gudbjornsson B, Skogseid B, Oberg K, Wide L, Hallgren R. Intact adrenocorticotropic hormone secretion but impaired cortisol response in patients with active rheumatoid arthritis. Effect of glucocorticoids. J Rheumatol 1996; 23: 596-602.
176. Cutolo M, Foppiani L, Perete C, Ballarino P, SuIIi A, Villaggio B et al. Hypothalamic-pituitary-adrenocortical axis function in premenopausal women with rheumatoid arthritis not treated with glucocortiocids. J Rheumatol 1999; 26: 282-288.
177. Crofford LJ, Kalogeras KT, Mastorakos G, Magiakou MA, Wells J, Kanik KS et al. Circadian relationships between interleukin (IL)-6 and hypothalamic-pituitary-adrenal axis hormones: failure of IL-6 to cause sustained hypercortisolism in patients with early untreated rheumatoid arthritis. J Clin Endocrinol Metab 1997; 82: 1279-1283.
178. Hall J, Morand EF, Medbak S, Zaman M, Perry L, Goulding NJ et al. Abnormal hypothalamic-pituitary-adrenal axis function in rheumatoid arthritis. Effects of nonsteroidal antiinflammatory drugs and water immersion. Arthritis Rheum 1994; 37: 1132-1137.
179. Harkness JA, Richter MB, Panayi GS, Van de Pette K, Unger A, Pownall R et al. Circadian variation in disease activity in rheumatoid arthritis. Br Med J (Clin Res Edn) 1982; 284: 551-554.
180. Morand EF, Leech M. Hypothalamic-pituitary-adrenal axis regulation of inflammation in rheumatoid arthritis. Immunol Cell Biol 2001; 79: 395-399.
181. Saldanha C, Tougas G, Grace E. Evidence for anti-inflammatory effect of normal circulating plasma cortisol. Clin Exp Rheumatol 1986; 4: 365-366.
182. Sanden S, Tripmacher R, Weltrich R, Rohde W, Hiepe F, Burmester GR et al. Glucocorticoid dose dependent downregulation of glucocorticoid receptors in patients with rheumatic diseases. J Rheumatol 2000; 27: 1265-1270.
183. Schlaghecke R, Kornely E, Wollenhaupt J, Specker C. Glucocorticoid receptors in rheumatoid arthritis. Arthritis Rheum 1992; 35: 740-744.
184. van Everdingen AA, Huisman AM, Wenting MJ, van Reesema S, Jacobs JW, Bijlsma JW. Down regulation of glucocorticoid receptors in early-diagnosed rheumatoid arthritis. Clin Exp Rheumatol 2002; 20: 463-468.
185. Huisman AM, Van Everdingen AA, Wenting MJ, Siewertsz Van Reesema DR, Lafeber FP et al. Glucocorticoid receptor downregulation in early diagnosed rheumatoid arthritis. Ann NY Acad Sci 2002; 966: 64-67.
186. Neeck G, Kluter A, Dotzlaw H, Eggert M. Involvement of the glucocorticoid receptor in the pathogenesis of rheumatoid arthritis. Ann NY Acad Sci 2002; 966: 491-495.
187. Eggert M, Kluter A, Rusch D, Schmidt KL, Dotzlaw H, Schulz M et al. Expression analysis of the glucocorticoid receptor and the nuclear factor-kB subunit p50 in lymphocytes from patients with rheumatoid arthritis. J Rheumatol 2002; 29: 2500-2506.
188. Straub RH, Paimela L, Peltomaa R, Scholmerich J, Leirisalo-Repo M. Inadequately low serum levels of steroid hormones in relation to interleukin-6 and tumor necrosis factor in untreated patients with early rheumatoid arthritis and reactive arthritis. Arthritis Rheum 2002b; 46: 654-662.
189. Brennan FM, Maini RN, Feldmann M. Role of pro-inflammatory cytokines in rheumatoid arthritis. Springer Semin Immunopathol 1998; 20: 133-147.
190. Verhoef CM, van Roon JA, Vianen ME, Lafeber FP, Bijlsma JW. The immune suppressive effect of dexamethasone in rheumatoid arthritis is accompanied by upregulation of interleukin 10 and by differential changes in interferon gamma and interleukin 4 production. Ann Rheum Dis 1999; 58: 49-54.
191. McEwen BS. The brain is an important target of adrenal steroid actions. A comparison of synthetic and natural steroids. Ann NY Acad Sci 1997; 823: 201-213.
192. Irwin M. Psychoneuroimmunology of depression: clinical implications. Brain Behav Immun 2002; 16: 1-16.
193. Webster JC, Oakley RH, Jewell CM, Cidlowski JA. Proinflammatory cytokines regulate human glucocorticoid receptor gene expression and lead to the accumulation of the dominant negative β isoform: a mechanism for the generation of glucocorticoid resistance. Proc Natl Acad Sci USA 2001; 98: 6865-6870.
194. Cutolo M, Seriolo B, Villaggio B, Pizzorni C, Craviotto C, Sulli A. Androgens and estrogens modulate the immune and inflammatory responses in rheumatoid arthritis. Ann NY Acad Sci 2002; 966: 131-142.
195. Cutolo M, Balleari E, Giusti M, Monachesi M, Accardo S. Sex hormone status of male patients with rheumatoid arthritis: evidence of low serum concentrations of testosterone at baseline and after human chorionic gonadotropin stimulation. Arthritis Rheum 1988; 31: 1314-1317.
196. Spector TD, Perry LA, Tubb G, Silman AJ, Huskisson EC. Low free testosterone levels in rheumatoid arthritis. Ann Rheum Dis 1988; 47: 65-68.
197. Seriolo B, Cutolo M, Garnero A, Accardo S. Relationships between serum 17 beta-oestradiol and anticardiolipin antibody concentrations in female patients with rheumatoid arthritis. Rheumatology (Oxford) 1999; 38: 1159-1161.
198. Grennan DM, Sanders PA, Thomson W, Dyer PA. Rheumatoid arthritis: inheritance and association with other autoimmune diseases. Dis Markers 1986; 4: 157-162.
199. Andonopoulos AP, Siambi V, Makri M, Christofidou M, Markou C, Vagenakis AG. Thyroid function and immune profile in rheumatoid arthritis. A controlled study. Clin Rheumatol 1996; 15: 599-603.
200. Shiroky JB, Cohen M, Ballachey ML, Neville C. Thyroid dysfunction in rheumatoid arthritis: a controlled prospective survey. Ann Rheum Dis 1993; 52: 454-456.
201. Bianchi G, Marchesini G, Zoli M, Falasconi MC, Iervese T, Vecchi F et al. Thyroid involvement in chronic inflammatory rheumatological disorders. Clin Rheumatol 1993; 12: 479-484.
202. Wellby ML, Kennedy JA, Pile K, True BS, Barreau P. Serum interleukin-6 and thyroid hormones in rheumatoid arthritis. Metabolism 2001; 50: 463-467.
203. Sternberg EM. Hyperimmune fatigue syndromes: diseases of the stress response? J Rheumatol 1993; 20: 418-421.
204. Postolache TT, Stiller JW, Herrel R, Goldstein DS, Sheeram SS, Zebrak R et al. Tree pollen peaks are associated with increased nonviolent suicide in women. Mol Psych advanced online publication, 14 December 2004.
205. Creed F. Psychological disorders in rheumatoid arthritis: a growing consensus? Ann Rheum Dis 1990; 49: 808-812.
206. Gorwood P, Pouchot J, Vinccneux P, Puechal X, Flipo RM, De Bandt M et al. Rheumatoid arthritis and schizophrenia: a negative association at a dimensional level. Schizophr Res 2004; 66: 21-29.
207. Dickens C, Jackson J, Tomenson B, Hay E, Creed F. Association of depression and rheumatoid arthritis. Psychosomatics 2003; 44: 209-215.
208. Blalock SJ, DeVellis RF. Rheumatoid arthritis and depression: an overview. Bull Rheum Dis 1992; 41: 6-8.
209. Mindham RH, Bagshaw A, James SA, Swannell AJ. Factors associated with the appearance of psychiatric symptoms in rheumatoid arthritis. J Psychosom Res 1981; 25: 429-435.
210. Zorrilla EP, Luborsky L, McKay JR, Rosenthal R, Houldin A, Tax A et al. The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain Behav Immun 2001; 15: 199-226.
211. Herbert TB, Cohen S. Depression and immunity: a meta-analytic review. Psychol Bull 1993; 113: 472-486.
212. Consensus development conference diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 1993; 94: 636-638.
213. Ziegler R, Kasperk C. Glucocorticoid-induced osteoporosis: prevention and treatment. Steroids 1998; 63: 344-348.
214. Cizza G, Ravn P, Chrousos GP, Gold PW. Depression: a major, unrecognized risk factor for osteoporosis? Trends Endocrinol Metab 2001; 12: 198-203.
215. Harper KD, Weber TJ. Secondary osteoporosis. Diagnostic considerations. Endocrinol Metab Clin N Am 1998; 27: 325-348.
216. Chrousos G, Gold PW. The concepts of stress and stress system disorders. Overview of physical and behavioral homeostasis. JAMA 1992; 267: 1244-1252.
217. Chan SD, Chiu DK, Atkins D. Mechanism of the regulation of the 1 alpha,25-dihydroxyvitamin D3 receptor in the rat jejunum by glucocorticoids. J Endocrinol 1984; 103: 295-300.
218. Mundy GR, Shapiro JL, Bandelin JG, Canalis EM, Raisz LG. Direct stimulation of bone resorption by thyroid hormones. J Clin Invest 1976; 58: 529-534.
219. Bisbocci D, Gallo V, Damiano P, Sidoli L, Cantoni R, Aitno G et al. Spontaneous release of interleukin 1 beta from human blood monocytes in thyrotoxic osteodystrophy. J Endocrinol Invest 1996; 19: 511-515.
220. Bartalena L, Brogioni S, Grasso L, Martino E. Increased serum interleukin-6 concentration in patients with subacute thyroiditis: relationship with concomitant changes in serum T4-binding globulin concentration. J Endocrinol Invest 1993; 16: 213-218.
221. Celik I, Akalin S, Erbas T. Serum levels of interleukin 6 and tumor necrosis factor-alpha in hyperthyroid patients before and after propylthiouracil treatment. Eur J Endocrinol 1995; 132: 668-672.
222. Lakatos P, Foldes J, Horvath C, Kiss L, Tatrai A, Takacs I et al. Serum interleukin-6 and bone metabolism in patients with thyroid function disorders. J Clin Endocrinol Metab 1997; 82: 78-81.
223. Simsek G, Karter Y, Aydin S, Uzun H. Osteoporotic cytokines and bone metabolism on rats with induced hyperthyroidism; changes as a result of reversal to euthyroidism. Chin J Physiol 2003; 46: 181-186.
224. Sato K, Han DC, Fujii Y, Tsushima T, Shizume K. Thyroid hormone stimulates alkaline phosphatase activity in cultured rat osteoblastic cells (ROS 17/2.8) through 3,5,3′-triiodo-L-thyronine nuclear receptors. Endocrinology 1987; 120: 1873-1881.
225. Britto JM, Fenton AJ, Holloway WR, Nicholson GC. Osteoblasts mediate thyroid hormone stimulation of osteoclastic bone resorption. Endocrinology 1994; 134: 169-176.
226. Abe E, Marians RC, Yu W, Wu XB, Ando T, Li Y et al. TSH is a negative regulator of skeletal remodeling. Cell 2003; 115: 151-162.
227. McLeod KJ, Rubin CT, Otter MW, Qin YX. Skeletal cell stresses and bone adaptation. Am J Med Sci 1998; 316: 176-183.
228. Kurihara N, Bertolini D, Suda T, Akiyama Y, Roodman GD. IL-6 stimulates osteoclast-like multinucleated cell formation in long term human marrow cultures by inducing IL-1 release. J Immunol 1990; 144: 4226-4230.
229. Pumarino H, Pumarino MG. Cytokines, growth factors, and metabolic bone disease. Rev Med Chile 1996; 124: 248-257.
230. Takeda S, Elefteriou F, Levasseur R, Liu X, Zhao L, Parker KL et al. Leptin regulates bone formation via the sympathetic nervous system. Cell 2002; 111: 305-317.
231. Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT et al. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 2000; 100: 197-207.
232. Harbuz MS, Windle RJ, Jessop DS, Renshaw D, Ingram CD, Lightman SL. Differential effects of psychological and immunological challenge on the hypothalamo-pituitary-adrenal axis function in adjuvant-induced arthritis. Ann NY Acad Sci 1999; 876: 43-52.
233. Sternberg EM, Young WSd, Bernardini R, Calogero AE, Chrousos GP, Gold PW et al. A central nervous system defect in biosynthesis of corticotropin- releasing hormone is associated with susceptibility to streptococcal cell wall-induced arthritis in Lewis rats. Proc Natl Acad Sci USA 1989b; 86: 4771-4775.
234. Aksentijevich S, Whitfield HJJ, Youag WSI, Wilder RL, Chrousos GP, Gold PW et al. Arthritis-susceptible Lewis rats fail to emerge from the stress hyporesponsive period. Dev Brain Res 1992; 65: 115-118.
235. Stefferl A, Linington C, Holsboer F, Reul JM. Susceptibility and resistance to experimental allergic encephalomyelitis: Relationship with hypothalamic-pituitary-adrenocortical axis responsiveness in the rat. Endocrinology 1999; 140: 4932-4938.
236. Misiewicz B, Poltorak M, Raybourne RB, Gomez M, Listwak S, Sternberg EM. Intracerebroventricular transplantation of embryonic neuronal tissue from inflammatory resistant into inflammatory susceptible rats suppresses specific components of infiammation. Exp Neurol 1997; 146: 305-314.
237. Diaz-Borjon A, Richaud-Patin Y, Alvarado de la Barrera C, Jakez-Ocampo J, Ruiz-Arguelles A, Llorente L. Multidrug resistance-1 (MDR-1) in rheumatic autoimmune disorders. Part II: increased P-glycoprotein activity in lymphocytes from systemic lupus erythematosus patients might affect steroid requirements for disease control. Jt Bone Spine 2000; 67: 40-48.
238. Lee YM, Fujiwara J, Munakata Y, Ishii T, Sugawara A, Kaku M et al. A mutation of the glucocorticoid receptor gene in patients with systemic lupus erythematosus. Tohoku Exp Med 2004; 203: 69-76.
239. Jiang T, Liu S, Tan M, Huang F, Sun Y, Dong X et al. The phase-shift mutation in the glucocorticoid receptor gene: potential etiologic significance of neuroendocrine mechanisms in lupus nephritis. Clin Chim Acta 2001; 313: 113-117.
240. Mingrone G, DeGaetano A, Pugeat M, Capristo E, Greco AV, Gasbarrini G. The steroid resistance of Crohn's disease. J Invest Med 1999; 47: 319-325.
241. Leung DY, Szefler SJ. Diagnosis and management of steroid-resistant asthma. Clin Chest Med 1997; 18: 611-625.
242. Barnes PJ. Inhaled glucocorticoids for asthma. N Engl Med 1995; 332: 868-875.